

32. (New) A nucleic acid according to claim 3 comprising at least 148 consecutive nucleotides of the nucleotide sequence set forth as SEQ ID NO:1, which consecutive nucleotides comprise nucleotides 1540-1542 (ACA) of SEQ ID NO:1.

33. (New) A nucleic acid according to claim 3 comprising at least 356 consecutive nucleotides of the nucleotide sequence set forth as SEQ ID NO:1, which consecutive nucleotides comprise nucleotides 1540-1542 (ACA) of SEQ ID NO:1.


34. (New) A nucleic acid according to claim 3, wherein the consecutive nucleotides are selected from the group consisting of nucleotides 1540-1557, 1540-1563, 1540-1675, 1540-1699, 1525-1542, 1519-1542, 1507-1542, 1483-1542, 1537-1545, 1534-1548, 1528-1554, 1516-1566, 1504-1554 and 1492-1568 of SEQ ID NO:1.

REMARKS

Claims 1, 2 and 10-28 are directed to polynucleotides encoding the polypeptides claimed in parent application 09/132,118 and contain the same limitations as claims 1, 2 and 10-28 as allowed in 09/132,118. The limitations of new claims 29-33 are found on p.4, line 2 and the limitations of new claim 34 are found on p.4, lines 11-24. These amendments introduce no new matter.

The Commissioner is hereby authorized to charge any fees or credit any overcharges, if necessary, relating to this communication to our Deposit Account No. 19-0750 (order no. T95-006-2).

Respectfully submitted,
SCIENCE & TECHNOLOGY LAW GROUP


Richard Aron Osman, Ph.D., #36,627
Tel: (650) 343-4341; Fax (650